ArticleJournal of ovarian research2026
DNA methylation-regulated AKAP12 expression modulates ECM remodeling and ADP/FAD ratio to influence prognosis in ovarian cancer.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOvarian cancer remains one of the deadliest cancers in women, characterized by poor prognosis and limited therapeutic options. The role of specific molecular factors, particularly in the context of tissue stem cells, DNA methylation, and metabolic reprogramming, is not fully understood. A-kinase anchoring protein 12 (AKAP12), a gene implicated in various cancers, has yet to be thoroughly explored in ovarian cancer. This study aims to investigate AKAP12’s involvement in ovarian cancer prognosis, focusing on its expression profile, regulation via DNA methylation, and its downstream metabolic effects.
methodsWe performed a comprehensive multi-omics analysis integrating single-cell RNA sequencing, Mendelian randomization (MR), and DNA methylation profiling, immune infiltration analysis and pathway enrichment analysis. First, we identified AKAP12 as a central prognostic gene in ovarian cancer by intersecting TCGA’s prognostic gene list with ovarian cancer stem cell marker genes. We examined AKAP12 expression in single-cell RNA sequencing data and analyzed the relationship between DNA methylation and AKAP12 expression. A multi-cohort analysis including datasets from TCGA and two independent GEO datasets (GSE26712 and GSE17260) further assessed AKAP12’s association in immune cell infiltration. Further mediated MR analysis was applied to determine the role of metabolic factors that mediate the role of AKAP12 on ovarian cancer. In silico virtual knockout of AKAP12 was performed on single-cell data to model its functional impact.
resultsAKAP12 was predominantly expressed in ovarian cancer stem cells and a subset of epithelial cells, contrasting with its expression in normal ovarian stromal cells. DNA methylation at loci cg10270306 and cg22942200 causally regulated AKAP12 expression and patient survival. The ADP/FAD (adenosine diphosphate/flavin adenine dinucleotide) ratio was identified as a key protective metabolic mediator, explaining 10.09% of AKAP12’s effect on prognosis. AKAP12-high tumors exhibited altered redox metabolism and ECM remodeling pathways. Critically, virtual knockout of AKAP12 causally disrupted the transcriptional network governing ECM composition and cell-ECM interactions.
conclusionOur study establishes AKAP12 as an upstream regulator of ovarian cancer progression, modulated by DNA methylation and exerting its effect through metabolic reprogramming (via the ADP/FAD ratio) and ECM remodeling. These findings provide new insights into the molecular mechanisms driving ovarian cancer and suggest therapeutic strategies targeting the AKAP12 regulatory network.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.